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Abstract
COVID-19 testing studies have become a standard approach for estimating prevalence
and fatality rates which then assist in public health decision making to contain and miti-
gate the spread of the disease. The sampling designs used are often biased in that they do
not reflect the true underlying populations. For instance, individuals with strong symp-
toms are more likely to be tested than those with no symptoms. This results in biased
estimates of prevalence (too high) and over-estimation of fatality rates. Typical post-
sampling corrections are not always possible. Here we present a simple bias correction
methodology derived and adapted from a correction for publication bias in meta analysis
studies. The methodology is general enough to allow a wide variety of customization
making it more useful in practice. Implementation is easily done using already collected
information. We show via an example that the bias corrections can provide dramatic
reductions in estimation error.
1. Introduction
There is an urgent need to better understand the spread of COVID-19 in popula-
tions both from being able to identify important changes in viral dynamics but also in
understanding the effectiveness of control and mitigation strategies. As has been said
repeatedly in the media, that until a vaccine or effective therapeutic is available, the only
real way forward is through tried and true public health measures that start with test-
ing, tracing and containment. So testing studies of multiple sorts have been undertaken
all over the world. Outside of a few exceptions however, most of these have been with
biased samples. These can be convenience samples which can lead to over representation
of symptomatic sampled units [1]. And this in turn can lead to over-estimation of fatal-
ity rates, among other things. For antibody serological studies which examine possible
past infections, the consequence of this is to over-estimate prevalence estimates. Even
attempts at random sampling can lead to biased samples due to differential response
rates.
Much attention has been focused on the issue of correcting for imperfect tests [3, 4];
but less attention has been paid to correcting for biased sampling. One notable exception
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is [1], where it was proposed a snowball sampling approach in conjunction with contact
tracing in order to set up a better disease surveillance system. However, this is not
how the vast majority of studies are conducted today. In this paper, we address biased
sampling from an entirely and somewhat unexpected viewpoint.
We note that biased samples also occur when doing meta analyses due to publication
bias [2]. That is, papers which favor a null hypothesis of no treatment effect are less
likely to be published and hence meta-analytic estimates of treatment effect can be over-
estimated. If the null-favoring censoring mechanism can be modeled, then interesting
corrections can be made. Based on [2], we derive and adapt a version of their model for
correcting testing bias in the current COVID-19 pandemic.
2. The model
Let p∗ ..=
(
p
(1)
1 , p
(2)
1 , p
(1)
2 , p
(2)
2 , . . . , p
(1)
M , p
(2)
M
)
be such that
M∑
s=1
(
p(1)s + p
(2)
s
)
= 1 and p(1)s , p
(2)
s ≥ 0, for s ∈ {1, . . . ,M}.
In other words, p∗ belongs to the standard 2M − 1 simplex. We observe a r.v. S∗ which
conditioned on p∗ has a categorical distribution in the interval (0, 1):
fS∗
(
s(i)|p∗
)
= p(i)s ,
where s ∈ {1, . . . ,M} represent symptomatology (e.g., different symptoms or different
degrees of symptoms) and i ∈ {1, 2} represents prevalence: i = 1 represents having
the virus, and i = 0 represents not having the virus. The proportion of people with
symptoms s = s(1) ∪ s(2) is given by
ps = p
(1)
s + p
(2)
s . (1)
Here p
(1)
s represents the probability of being in the category s and having the virus,
whereas p
(2)
s represents the probability of being in the category s and not having the
virus.
From this notation, the overall probability of having the virus is
p
(1)
1 + · · · p(1)M .
Also, p
(1)
s /ps is the conditional probability of having the virus given that the person is
in the category s of symptoms.
We assume a Bernoulli r.v. T , which will be 1 with probability p(S∗) (i.e., each subset
of S∗ can assign different probability of success to T .). This T will tell us whether the
person is tested (success) or not (failure). Without loss of generality, let us assume an
ordering of S∗ by severity and/or number of symptoms. Then we obtain also the four
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following orderings:
p(1) ≤ · · · ≤ p(s) ≤ · · · ≤ p(M), (2)
p
(
1(1)
)
≤ · · · ≤ p
(
s(1)
)
≤ · · · ≤ p
(
M (1)
)
, (3)
p
(1)
1
p1
≤ · · · ≤ p
(1)
s
ps
≤ · · · ≤ p
(1)
M
pM
, (4)
p1 ≥ · · · ≥ ps ≥ · · · ≥ pM . (5)
The intuition behind this is that the higher the degree and/or number of symptoms,
then the higher the probability of being tested (Eq. 2), the higher the probability of
testing people with the virus (Eq. 3), the higher the probability of having the virus (Eq.
4), and the lower the real population proportion of people with the symptoms (Eq. 5).
From the conditional distribution of (S∗|p∗, T = 1), we observe i.i.d. draws of S|p,
whose density, because of Bayes theorem, is
fS|p(s|~p) = fS∗|p∗,T (s|~p, 1) =
P [T = 1|S∗ = s,p∗ = ~p]
P [T = 1|p∗ = ~p] fS∗|p∗ (s|~p)
=
p(s)
E[p(S∗)|p∗ = ~p]ps. (6)
Assume there is no error in testing. Then we know exactly the proportion of infected
people in the sample. Moreover, we know under which category s is each person tested.
Therefore, for all s, we can derive:
fS|p
(
s(1)|~p
)
= fS∗|p∗,T
(
s(1)|~p, 1
)
=
P
[
T = 1|S∗ = s(1),p∗ = ~p]
P [T = 1|p∗ = ~p] fS∗|p∗
(
s(1)|~p
)
=
p
(
s(1)
)
E[p(S∗)|p∗ = ~p]p
(1)
s . (7)
Thus, we obtained in Eq. 6 the biased estimate of the proportion of people tested
—and in Eq. 7 the biased estimate of the proportion of prevalence) for each s—. The
total biased estimator of tested people is
M∑
s=1
p(s)
E[p(S∗)|p∗ = ~p]ps, (8)
and the total biased estimator of prevalence is
M∑
s=1
p
(
s(1)
)
E[p(S∗)|p∗ = ~p]p
(1)
s . (9)
3. Bias correction
The bias correction is easily determined. It amounts to multiplying the quantity on
the LHS of Eqs. 6 and 7 by the inverse of the quotient on the RHS of each respective
3
equation. Specifically, the bias correction is given by C(x)fS|p(x|~p), where
C(x) ..=
P [T = 1|p∗ = ~p]
p(x)
. (10)
Replacing x by s and s(1) will give us the bias correction for testing and prevalence,
respectively, for each s. Summing over s gives the testing bias-corrected estimate of
disease prevalence. Now, the numerator at the RHS of Eq. 10 can be estimated as NT /N ,
where NT is the number of people tested, and N is the census population. However, the
denominator is unknown, but we still can say some things depending on the size of s.
3.1. Big s
The bias problem of testing and prevalence is not in the last values of S∗, but in
considering only the last values of S∗ for testing. This is the main thing to correct.
We already learned that the overall proportion of people tested is NT /N . We also
know that most of the people tested are symptomatic; therefore, when s approaches M ,
p˜s ..= NT /NfS|p(s|~p) is a good estimator of the real proportion of the last value. Finally,
since we know that most of the symptomatic people will have the virus, and most of
them will get tested, then p˜
(1)
s ≈ p˜s for large s.
3.2. Small s
When s decreases to 1, the situation is different. According to Eq. 2, in the absence
of symptoms, the probability of being tested is small. Nonetheless, having few tests for
small values of s does not mean that the proportion of people infected/uninfected is close
to 0. I.e., p(s) might be small, but ps is large, which according to Eq. 6 is introducing a
heavy bias. Another way to think of this is that for an unbiased sample, ps would have
a clear representation.
Now, notice that, since 1 ≥ C(s)fS|p(s|~p), it is possible to give a lower bound for
p(s):
NT
N
fS|p(s|~p) ≤ p(s) (11)
Giving p(s) its lower possible value makes the corrected estimate C(s)fS|p(s|~p) = 1.
However, this implies that for all s′ 6= s, the estimated probability of being tested is 0,
which cannot be true.
In order to solve this, let’s partition S∗ into three groups: S∗ = S− ∪ Sm ∪ S+,
where S− and S+ are the subsets of low and high values of S∗, respectively; and Sm,
the symptoms in between.
According to Section 3.1, we have already estimated the probability of the elements
in S+. Thus making p+ ..=
∑
s∈S+ p˜s, we propose the following solution for small values
of s:
1. Take the space S− ∪ Sm, which has probability 1− p+.
2. Letting M˜ be the cardinality of the set S− ∪ Sm, assign equal probabilities p˜s to
all s ∈ S− ∪ Sm (by maximum entropy). I.e., p˜s = (1− p+) /M˜ .
Notice that using maxent is justified because, as E. T. Jaynes put it, “the maximum-
entropy estimate... is the least biased estimate on the given information” [5].
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3.2.1. Prevalence
We know that in the asymptomatic population, a non-negligible portion of individuals
has the virus. However, studies vary here as for the proportion of asymptomatic people
with the virus. Some of those studies maintain that most of the asymptomatic people
are already infected. In such case, p
(1)
s ≈ ps, as we explained in Subsection 3.2.
Others lean on the side that, for small, s, we have p
(1)
s /ps closer to 0 than to 1, but
not necessarily approaching 0. In this scenario, we propose the following algorithm:
1. Generate a random number u according to a uniform distribution in the interval
(0, 1/2).
2. Make up˜s = p˜
(1)
s .
Remark 1. We have randomized u in (0, 1/2). But it is possible, in case of total ignorance
regarding p
(1)
s /ps, to stretch u to be in the interval (0, 1). Actually, depending on our
knowledge, we can just randomize u in whatever interval is suitable to our needs, and
use it to estimate p
(1)
s .
3.3. Middle values of s
Notice that in the previous algorithm we are not asking to use p˜ for the correction in
Eq. 10 of values in Sm (although it might be done with some care.) This is because for
these values we have few knowledge. Our recommendation is to collapse S∗ to S− ∪ S+.
In fact, when S∗ is comprised of only two values, symptomatic and non-symptomatic,
say, the estimation of Section 3.1 is enough to estimate the non-symptomatic as 1 −
(NT /N)fS|p(s|~p).
3.4. Some model caveats
The model is presented in some generality on purpose. It naturally permits cus-
tomization to different testing settings. For instance, symptomatology may be extended
to reflect different subpopulations (e.g. racial/ethnic subgroups, age groups, risk groups,
environments). The model can also be generalized to index more than 1 type of test (not
shown here).
4. Estimated variance
Let X1, . . . ,Xn be iid multinomial M (1;p
∗). Then
∑n
i=1Xi ∼ M(n;p∗). Let pˆ ..=
n−1
∑n
i=1Xi. By the MCLT, we know that
√
n · pˆ ∼ AN (p∗,Σ/n) , (12)
where AN stands for asymptotically normal, and Σ = Diag(p∗)− p∗p∗T .
Now define
fp
..=
(
fS|p
(
s
(1)
1 |~p
)
, fS|p
(
s
(2)
1 |~p
)
, . . . , fS|p
(
s
(1)
M |~p
)
, fS|p
(
s
(2)
M |~p
))
,
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and let Y1, . . . ,Yn be iid M (1; fp), so that
∑n
i=1Yi ∼ M(n; fp). Applying the Delta
method to qˆ = n−1
∑n
i=1Yi, we obtain that
√
n · qˆ ∼ AN(fp,Vn), where Vn =
1
n
g′(p)Σg′(p)T , and g′(p) is
g′(p) =
1
P [T = 1|p = ~p]
(
p
(
s
(1)
1
)
, p
(
s
(2)
1
)
, . . . , p
(
s
(1)
M
)
, p
(
s
(2)
M
))
. (13)
Notice that the correction in Eq. 10 applies g−1 to Y, which leads back to X.
Therefore, asymptotically, we obtain again the distribution in Eq. 12.
In practice, we start with the biased iid Y˜1, . . . , Y˜NT , which are M(1, fp), whose
sum is M(n, fp). Letting q˜ = N
−1
T
∑
Y˜i, we have again by the MCLT that
√
NT · q˜ ∼
AN(fp,VNT ). Making h(fp) = C · fp, where C is a vector with components as in Eq.
10, we can apply again the Delta method to h, obtaining
√
NT · q˜ ∼ AN
(
h(fp),CVNTC
T
)
. (14)
However, since we are not using C, but C, an M -vector whose last component is
(NT /N)fM and with the first M − 1 components being all 1M−1
(
1− NT
N
fM
)
. Then, the
variance-covariance matrix becomes


aσ2M aσ
2
M · · · bσ2M
aσ2M aσ
2
M · · · bσ2M
...
...
. . .
...
aσ2M aσ
2
M · · · bσ2M
bσ2M bσ
2
M · · · cσ2M


,
where c =
(
NT
N
)2
, a = c
(
1
M−1
)2
, b = c
M−1 , and σ
2
M is the variance of fM . From this,
the estimated variance of the total prevalence estimate can be calculated.
5. Toy Example
Let’s consider a population of size one million where individuals are labeled as asymp-
tomatic (S∗ = 1), few symptoms (S∗ = 2), mild symptoms (S∗ = 3), and all symptoms
(S∗ = 4). According to our previous definitions let’s consider the following probabilities:
p1 = 0.5 p2 = 0.25 p3 = 0.15 p4 = 0.1
p
(1)
1 = 0.05 p
(1)
2 = 0.05 p
(1)
3 = 0.075 p
(1)
4 = 0.09
p
(2)
1 = 0.45 p
(2)
2 = 0.2 p
(2)
3 = 0.075 p
(2)
4 = 0.01
p
(
1(1)
)
= 0.001 p
(
2(1)
)
= 0.01 p
(
3(1)
)
= 0.1 p
(
4(1)
)
= 0.9
p
(
1(2)
)
= 0.001 p
(
2(2)
)
= 0.01 p
(
3(2)
)
= 0.1 p
(
4(2)
)
= 0.05
p(1) = 0.001 p(2) = 0.01 p(3) = 0.1 p(4) = 0.815
None of these values is known to the researcher. The first row is the proportion of
people in each group, it adds to 1. The second (third) are the population proportion
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of infected (non-infected). Notice that the total prevalence is
∑
p
(1)
i = 0.265. The
fourth is the proportion of tested people with the disease in each group. The fifth is
the proportion of non-infected tested people in each group. The sixth is the resulting
proportion of people tested within each group, it is derived using all the other rows. The
proportion of tested people is
P [T = 1|p∗ = ~p] =
4∑
i=1
p(i)pi = 0.0995. (15)
The researcher does not know this probability, but knows the total number of people
tested (which can also be derived easily to be NT = 99, 500), and the overall census
population N = 1, 000, 000, with which she can estimate it. In addition, each individual’s
symptomatology status and test result is known. Thus the proportion of people tested
in each group is:
fS|p(1|~p) = fS∗|p∗,T (1|~p, 1)
=
P [T = 1|S∗ = 1,p = ~p]
P [T = 1|p = ~p] fS∗|p(1|~p)
=
0.001(0.5)
0.0995
≈ 0.005,
fS|p(2|~p) =
0.01(0.25)
0.0995
≈ 0.025,
fS|p(3|~p) =
0.1(0.15)
0.0995
≈ 0.15,
fS|p(4|~p) =
0.815(0.1)
0.0995
≈ 0.82.
Notice that the last term is grossly overestimated as 0.82 (against the real 0.1), and
the first two terms are grossly underestimated (against the real 0.5, 0.25); the third
term is very well approximated, but in practice we do not know it. However, since
we know that most of NT is made of the last group, (NT /N)0.82 = 0.0815 becomes a
good estimator of its size. According to our proposal for the small values of S, take
1 − (Nt/N)fS|p(4|~p) = 0.918, and by maxent, distribute it equally among the three
remaining groups. In this way, we obtain a probability of 0.306 for each of the first
three groups. This corrects greatly for p1 and p2, but is perjudicial for p3, which is now
overestimated since its original value was the right one. According to Subsubsection
3.2.1, we take three uniform random values between (0, 0.5), so for the purpose of our
example let’s consider the averages u1 = u2 = u3 = 0.25. Thus we estimate p
(1)
1 =
p
(1)
2 = p
(1)
3 = 0.0765. Since in the last group we assume that p
1
4 ≈ p4, we obtain a total
prevalence of 0.311 (against the real 0.265). The naive estimator of prevalence produces∑4
i=1 p
(
i(1)
)
pi/0.0995 = 0.8949.
In this case, we do not need to collapse the data for two reasons: we have a small
amount of groups and we are using the same u for all of them, so collapsing will produce
the same values. In real life, we should randomize ui for each group i. Thus, the bigger
the number of groups with different sizes and different proportions p
(1)
i /pi, the corrected
estimate in the middle groups will become more irrelevant. Jumping to only two groups
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allows us to estimate the first one as the complement of the last one, facilitating the
analysis.
6. The need for further bias correcting and discussion
The model assumes tests with no errors (i.e. false positives or false negatives). Clearly
this is not the situation in practice. Specificities and sensitivities can often be less than
ideal. Testing bias-corrected estimates of prevalence can be further corrected in a second
stage using the methods of Diggle2011 [3] or Greenland1996 [4] which account for using
imperfect tests.
Our study demonstrates that under biased sampling designs that are often difficult to
avoid in testing studies for COVID-19, that the resulting biased estimates of prevalence
can be corrected using simple methodology derived and adapted from corrections for
publication bias used in meta analysis studies. The correction detailed in our toy example,
while extreme, shows the effectiveness of the correction. The corrections can be used
directly in practice using the data collected even though many of underlying quantities
in the population may be unknown to the researcher.
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